Short answer
PROTHENA CORP PUBLIC LTD CO (PRTA) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $1M (down 77.1% year over year) with net income of −$19M.
Q2 2026 key financials · XBRL
- Revenue
- $1M
- −77.1% YoY · −98.0% QoQ
- Net income
- −$19M
- +85.2% YoY · −156.8% QoQ
- Operating margin
- -2089.2%
- EPS (diluted)
- −$0.34
- +85.4% YoY · −156.7% QoQ
Source: XBRL data from the PROTHENA CORP PUBLIC LTD CO (PRTA) Q2 2026 10-Q on SEC EDGAR. USD.
PROTHENA CORP PUBLIC LTD CO Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- 2026 operating and investing cash use outlook: approximately $18 million–$23 million
- Contractual obligations $9.446 million, including operating leases $7.484 million
- Brisbane sublease obligations $14.9 million, with approximately $7.4 million outstanding
- No off-balance-sheet arrangements as of June 30, 2026
Risk Factors
- No material changes stated from 2025 Form 10-K; risks remain substantially carried forward
- Accumulated deficit $1.3 billion despite six-month net income of $14.1 million
- Additional capital required; cash and equivalents $288.2 million expected to fund operations for at least twelve months
- Privacy compliance exposure under GDPR, with penalties up to €20 million or 4% of global annual turnover
- Clinical development risk from Phase 3 prasinezumab, Phase 3 coramitug, Phase 2 moponetug, and Phase 1 PRX019 trials
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PROTHENA CORP PUBLIC LTD CO quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.